• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

H5N1 Vaccine Clinical Trials - Virus Like Particles

sharon sanders

Editor-in-Chief & President
hat tip Laidback Al - transferred from FluTrackers.org

H5N1 Vaccine Clinical Trials <hr style="color: rgb(209, 209, 225); background-color: rgb(209, 209, 225);" size="1"> Medicago is a biotechnology firm located inQu?bec City, Qu?bec, Canada. Here is a press release from the company.

Medicago updates on progress with Phase II clinical testing of its avian influenza vaccine candidate

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). The Company expects to present interim Phase II clinical trial results with its H5N1 pandemic influenza vaccine in January, 2011.
. . . .

http://www.prnewswire.com/news-relea...112307829.html
 
Back
Top Bottom